MAY 14, 2018 1:50 PM PDT

Early Differences Between Benign and Malignant Tumors

WRITTEN BY: Kara Marker

Physicians are in need of a dependable diagnostic approach for distinguishing between benign and malignant tumors early-on. Once doctors can rule out that a tumor is malignant, they can save a patient from undergoing the often harsh, grueling treatments prescribed to treat malignant cancer.

Micrograph of lymph node with colorectal carcinoma. Credit: Wikimedia user Nephron

In a new study from scientists at the Duke University Medical Center, clear differences have been observed between early benign and early malignant tumors. Researchers found that malignant cancers are “born to be bad,” and they are working on identifying what makes them “bad” as soon as possible.

"We found evidence that benign and malignant tumors start differently, and that cell movement - an important feature of malignancy - manifests itself very early on during tumor growth," explained lead author Marc D. Ryser, PhD.

Abnormal cell movement is what causes tumors to spread, or metastasize, to different tissues, which makes them more dangerous. In the past, research has shown that significant qualities of a tumor are present in the genome from start to finish. In the new study, researcher analyzed 19 human colorectal tumors with both genome sequencing technology and mathematical simulation models.

They successfully identified signatures of early abnormal cell movement in nine out of 15 invasive samples. No early abnormal cell movement was detected in the four benign tumors. Ryser and the others acknowledge that they need to confirm their findings in a larger study.

"Thanks to improved screening technologies, we diagnose more and more small tumors," explained senior author Darryl Shibata, MD. "Because treating a patient aggressively can cause them harm and side-effects, it is important to understand which of the small screen-detected tumors are relatively benign and slowly growing, and which ones are born to be bad."

Indeed, the key clinical application that the study scientists want to develop as a result of their research is to test small tumors that have been detected by a cancer screening for early cell movement that could indicate malignancy. The ultimate goal? Save the aggressive therapies for the people who actually need it.

The present study was published in the journal Proceedings of the National Academy of Sciences.

Source: Duke University Medical Center

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 13, 2019
Health & Medicine
NOV 13, 2019
Sherlock's DNA biosensors set to make diagnostics elementary
The anxious wait to receive results from expensive diagnostic laboratory tests could soon be a thing of the past thanks to a technological breakthrough. En...
JAN 15, 2020
Clinical & Molecular DX
JAN 15, 2020
Laser microchip picks up cancer markers in urine
A future where patients no longer need to endure expensive, painful and complicated cancer tests could soon become a reality. Researchers have developed a...
FEB 15, 2020
Clinical & Molecular DX
FEB 15, 2020
FDA nod for AI-powered technology to detect strokes
The US Food and Drug Administration (FDA) has provided clearance for a novel technology that uses artificial intelligence (AI) to detect strokes. The platf...
MAR 02, 2020
Clinical & Molecular DX
MAR 02, 2020
Bluetooth-enabled skin patch monitors diabetics' glucose levels
A new wearable skin patch could completely transform daily glucose tracking routines for diabetics. This innovation, developed by the UK-based company Nema...
MAR 24, 2020
Clinical & Molecular DX
MAR 24, 2020
Ultra sensitive cancer diagnostic detects DNA "fingerprints" in liquid biopsies
  Researchers from the Broad and Dana-Farber Cancer Institutes have developed a diagnostic technology that can monitor for the presence of recurring c...
MAR 30, 2020
Clinical & Molecular DX
MAR 30, 2020
Imaging Platform to Aid in Diagnosis of COVID-19
In the exponential growth of a rapidly spreading infectious disease, healthcare systems become overwhelmed, which can have a cascade of negative effects....
Loading Comments...